influence and gained access to inside information. Steve Fraidin, our Vice Chairman, was invited to join the board on March 9th along with two other new directors: Dr. Fred Eshelman, a pharmaceutical industry entrepreneur, and Thomas W. Ross, former president of UNC and a former Superior Court judge.
Date: Mar 24, 2016
Category: Business
Source: Google
Valeant Pharma (VRX) Announces Addition on Three Independent Directors
Fred Eshelman is a 35-year veteran of the pharmaceutical industry and is the founder and former Chief Executive Officer and Executive Chairman of Pharmaceutical Product Development, Inc. (formerly NASDAQ: PPDI). Dr. Eshelman was also the founding chairman of Furiex Pharmaceuticals, Inc., a drug deve
Date: Mar 09, 2016
Category: Business
Source: Google
Valeant Pharma adds hedge fund executive, 2 others to board
The Canadian drugmaker says Pershing Vice Chairman Stephen Fraidin is joining its board, along with pharmaceutical executive Dr. Fred Eshelman and former University of North Carolina president Thomas W. Ross. Dr. Anders Lonner also is leaving. These moves will bump the board's size to 14 members.
Date: Mar 09, 2016
Source: Google
Valeant Adds 3 Directors, Including a Pershing Executive
Ackmans Pershing Square Capital Management LP, one of the drugmakers biggest shareholders, gained a board seat for Stephen Fraidin, its vice chairman. Also joining are Fred Eshelman, the former chief executive officer of Pharmaceutical Product Development Inc. and Thomas W. Ross, the formerpresid
Date: Mar 09, 2016
Category: Business
Source: Google
Valeant names 3 new members to its board, stock rises 4%
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that Dr. Fred Eshelman, Mr. Stephen Fraidin and Mr. Thomas W. Ross, Sr. have joined its Board of Directors as independent directors, effective March 8, 2016. Valeant also announced that Dr. Anders Lonner has stepped
Date: Mar 09, 2016
Category: Business
Source: Google
Valeant enlarges board to 14 members; three new directors and one departure
Also joining the board is Fred Eshelman, the founder and former chief executive and executive chairman of Pharmaceutical Product Development Inc., and former University of North Carolina president Thomas Ross.
Three candidates the Canadian drugmaker is considering, the people said, are Fred Eshelman, a veteran pharmaceuticalexecutive; Stephen Fraidin, a senior executive at William Ackman's Pershing Square Capital Management LP, a majorValeant shareholder; and Thomas Ross, former president of the Univers
Furiex Pharmaceuticals Inc. founded in 1985 by Fred Eshelman as a spinoff of PPD, which he also founded reported in a joint announcement with Forest Laboratories Inc. Monday that it has entered into a definitive agreement to be acquired by New York City-based Forest. Purchase price, according to